HLS Therapeutics Inc (CVE:HLS) reached a new 52-week high on Thursday . The stock traded as high as C$16.10 and last traded at C$16.04, with a volume of 33149 shares. The stock had previously closed at C$15.75.
The company has a quick ratio of 2.17, a current ratio of 2.30 and a debt-to-equity ratio of 69.24.
HLS Therapeutics (CVE:HLS) last posted its quarterly earnings data on Wednesday, August 15th. The company reported C($0.03) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of C($0.15) by C$0.12. The firm had revenue of C$21.04 million for the quarter, compared to the consensus estimate of C$20.77 million. Equities analysts anticipate that HLS Therapeutics Inc will post -0.04 earnings per share for the current year.
WARNING: This report was reported by BBNS and is the property of of BBNS. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://baseballnewssource.com/2018/11/10/hls-therapeutics-hls-hits-new-12-month-high-at-16-10/2972371.html.
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and distributes pharmaceutical products in North American markets. It is focused on treatment products for the central nervous system and cardiovascular specialties. The company was incorporated in 2014 and is headquartered in Toronto, Canada.
See Also: What is the Rule of 72?
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.